Answers are grounded in this paper and cite their sources.
Objective: To evaluate vision-related quality of life (QoL) using National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) in neovascular age-related macular degeneration (nAMD) patients during coronavirus disease-2019 (COVID-19) pandemic. Material and Methods: nAMD patients whose intravitreal injection had to be postponed due to restrictions of COVID-19 lockdown between April and June 2020, NEI-VFQ-25 was administered last visit pre-COVID-19 and first visit during COVID-19. NEI-VFQ-25 scores, best-corrected visual acuity (BCVA) and central macular thickness (CMT) were compared between visits. Results: Fifty six patients with nAMD were participitated in the study. The composite score of NEIVFQ-25 was statistically significantly lower at first visit during COVID-19 when compared with at last pre-COVID-19 (95% confidence interval, 2.33-4.24; p=0.000). Decrease in NEI-VFQ-25 composite score was moderately associated with an impairment in BCVA at first visit during COVID-19 and duration of treatment delay after adjusting for age, gender, BCVA at last visit pre COVID-19 and CMT (β coefficient=0.42 and 0.41 and p=0.016 and 0.015). Conclusion: Negative impacts of delayed treatment during COVID-19 pandemic were observed by decrease NEI-VFQ-25 composite scores in patients with nAMD observed on psychological well-being and ability of performing daily life activities that depend on visual function.
No takes yet. Share an insight, caveat, or question.
Timur et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: